Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087016656> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2087016656 endingPage "91" @default.
- W2087016656 startingPage "91" @default.
- W2087016656 abstract "Metastasis of prostate cancer to bone is a common complication of progressive prostate cancer. Skeletal metastases are often associated with severe pain and thus demand therapeutic interventions. Although often characterized as osteoblastic, prostate cancer skeletal metastases usually have an underlying osteoclastic component. Advances in osteoclast biology and pathophysiology have led toward defining putative therapeutic targets to attack tumor-induced osteolysis. Several factors have been found to be important in tumor-induced promotion of osteoclast activity. One key factor is the protein receptor activator of nuclear factor-kappa B ligand (RANKL), which is required to induce osteoclastogenesis. RANKL is produced by prostate cancer bone metastases, enabling these metastases to induce osteolysis through osteoclast activation. Another factor, osteoprotegerin, is a soluble decoy receptor for RANKL and inhibits RANKL-induced osteoclastogenesis. Osteoprotegerin has been shown in murine models to inhibit tumor-induced osteolysis. In addition to RANKL, parathyroid hormone-related protein and interleukin-6 are produced by prostate cancer cells and can promote osteoclastogenesis. Finally, matrix metalloproteinases (MMPs) are secreted by prostate cancer cells and promote osteolysis primarily through degradation of the nonmineralized bone matrix. MMP inhibitors have been shown to diminish tumor establishment in bone in murine models. Thus, many factors derived from prostate cancer metastases can promote osteolysis, and these factors may serve as therapeutic targets. The importance of osteoclasts in the establishment and progression of skeletal metastases has led to clinical evaluation of therapeutic agents to target them for slowing metastatic progression. Bisphosphonates are a class of compounds that decrease osteoclast life span by promoting their apoptosis. The bisphosphonate pamidronate has proven clinical efficacy for relieving bone pain associated with breast cancer metastases and has a promising outlook for prostate cancer metastases. Another bisphosphonate, zoledronic acid, appears to directly target prostate cancer cells in addition to diminishing osteoclast activity at the metastatic site. In addition to bisphosphonates, other novel therapies based on studies that delineate mechanisms of skeletal metastases establishment and progression will be developed in the near future." @default.
- W2087016656 created "2016-06-24" @default.
- W2087016656 creator A5056820426 @default.
- W2087016656 date "2002-01-01" @default.
- W2087016656 modified "2023-09-24" @default.
- W2087016656 title "The role of osteoclastic activity in prostate cancer skeletal metastases" @default.
- W2087016656 doi "https://doi.org/10.1358/dot.2002.38.2.820105" @default.
- W2087016656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12532187" @default.
- W2087016656 hasPublicationYear "2002" @default.
- W2087016656 type Work @default.
- W2087016656 sameAs 2087016656 @default.
- W2087016656 citedByCount "48" @default.
- W2087016656 countsByYear W20870166562013 @default.
- W2087016656 countsByYear W20870166562014 @default.
- W2087016656 countsByYear W20870166562018 @default.
- W2087016656 countsByYear W20870166562019 @default.
- W2087016656 countsByYear W20870166562022 @default.
- W2087016656 crossrefType "journal-article" @default.
- W2087016656 hasAuthorship W2087016656A5056820426 @default.
- W2087016656 hasConcept C121608353 @default.
- W2087016656 hasConcept C126322002 @default.
- W2087016656 hasConcept C141071460 @default.
- W2087016656 hasConcept C143998085 @default.
- W2087016656 hasConcept C170493617 @default.
- W2087016656 hasConcept C2776033226 @default.
- W2087016656 hasConcept C2777783956 @default.
- W2087016656 hasConcept C2779013556 @default.
- W2087016656 hasConcept C2779428903 @default.
- W2087016656 hasConcept C2780192828 @default.
- W2087016656 hasConcept C2780426850 @default.
- W2087016656 hasConcept C2781282405 @default.
- W2087016656 hasConcept C502942594 @default.
- W2087016656 hasConcept C673006 @default.
- W2087016656 hasConcept C71924100 @default.
- W2087016656 hasConcept C88045685 @default.
- W2087016656 hasConceptScore W2087016656C121608353 @default.
- W2087016656 hasConceptScore W2087016656C126322002 @default.
- W2087016656 hasConceptScore W2087016656C141071460 @default.
- W2087016656 hasConceptScore W2087016656C143998085 @default.
- W2087016656 hasConceptScore W2087016656C170493617 @default.
- W2087016656 hasConceptScore W2087016656C2776033226 @default.
- W2087016656 hasConceptScore W2087016656C2777783956 @default.
- W2087016656 hasConceptScore W2087016656C2779013556 @default.
- W2087016656 hasConceptScore W2087016656C2779428903 @default.
- W2087016656 hasConceptScore W2087016656C2780192828 @default.
- W2087016656 hasConceptScore W2087016656C2780426850 @default.
- W2087016656 hasConceptScore W2087016656C2781282405 @default.
- W2087016656 hasConceptScore W2087016656C502942594 @default.
- W2087016656 hasConceptScore W2087016656C673006 @default.
- W2087016656 hasConceptScore W2087016656C71924100 @default.
- W2087016656 hasConceptScore W2087016656C88045685 @default.
- W2087016656 hasIssue "2" @default.
- W2087016656 hasLocation W20870166561 @default.
- W2087016656 hasLocation W20870166562 @default.
- W2087016656 hasOpenAccess W2087016656 @default.
- W2087016656 hasPrimaryLocation W20870166561 @default.
- W2087016656 hasRelatedWork W153206471 @default.
- W2087016656 hasRelatedWork W1994680131 @default.
- W2087016656 hasRelatedWork W2018450202 @default.
- W2087016656 hasRelatedWork W2028064456 @default.
- W2087016656 hasRelatedWork W2065184790 @default.
- W2087016656 hasRelatedWork W2087016656 @default.
- W2087016656 hasRelatedWork W21132798 @default.
- W2087016656 hasRelatedWork W2117150911 @default.
- W2087016656 hasRelatedWork W2907221685 @default.
- W2087016656 hasRelatedWork W4281740695 @default.
- W2087016656 hasVolume "38" @default.
- W2087016656 isParatext "false" @default.
- W2087016656 isRetracted "false" @default.
- W2087016656 magId "2087016656" @default.
- W2087016656 workType "article" @default.